Outsmarting data bottlenecks in pharma: The clinical terminology advantage
Read time: 7 min
Summary
The pharmaceutical research industry is changing rapidly. As the need for real-world evidence (RWE) grows, so does the ability to produce (and reproduce) accurate, reliable, and timely insights. But it’s not that simple.
Most health data is fragmented and unstructured, containing errors and inconsistent coding and terminology. The result? Stalled progress, costly bottlenecks, and serious data quality concerns.
This insight brief explores how reliable sources of truth like IMO Health’s standardized clinical terminology and precise normalization tools can help combat stubborn research challenges and reveal the full potential of clinical and real-world data.
What You'll Learn
Why common evidence generation workflows, like literature review and patient cohorting, often stall due to fragmented data and inconsistent terminology
How AI-powered normalization and structured terminology help reduce bias, improve reproducibility, and accelerate time to evidence
A concrete example that demonstrates how a real organization transformed their approach to generating high-quality, scalable insights
Featured speaker(s)
April Curtis
Marketing Director
IMO
Thomas Magnum
Marketing Manager
IMO
B.A. Baracus
Data Analyst
IMO
B.A. Baracus
Data Analyst
IMO
Who It's For
Download the insight brief
Optional Section Title
This is a full-width section inside a light grey background, styled using only inline styles and Bootstrap classes.
